NCT05774899 - CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

Adenoid Cystic CarcinomaMetastatic Adenoid Cystic CarcinomaRecurrent Adenoid Cystic Carcinoma

Interventions

DRUG

CB-103

First-in-class pan-NOTCH inhibitor, capsule taken orally.

DRUG

Abemaciclib

CDK4/6 inhibitor, tablet taken orally.

DRUG

Lenvatinib

Per standard care, capsule taken orally.

Trial Locations (1)

RECRUITING

Dana Farber Cancer Institute, Boston